Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ELANE | P08246 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | USP5 | P45974 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27637403 | 0.92 | KMT2A (0.51) | KMT2AELANEHSD17B10PDE4BCYP1A2 | |
| Acetic Acid Phenyl Ester SCHEMBL30176020 | 0.90 | NR4A2 (0.67) | KMT2AELANEHSD17B10CYP1A2ALDH1A1 | |
| SCHEMBL8655921 | 0.84 | ELANE (0.59) | KMT2AELANEHSD17B10PDE4BALDH1A1 | |
| SCHEMBL503582 | 0.81 | PDE4B (0.80) | KMT2AHSD17B10PDE4BCYP1A2ALDH1A1 | |
| SCHEMBL10885925 | 0.81 | NR4A2 (0.63) | KMT2AHSD17B10PDE4BCYP1A2ALDH1A1 | |
| SCHEMBL9049629 | 0.80 | NPC1 (0.74) | KMT2AELANEHSD17B10ALDH1A1RAB9A | |
| SCHEMBL10353454 | 0.80 | NR4A2 (0.81) | KMT2AHSD17B10PDE4BCYP1A2ALDH1A1 | |
| SCHEMBL11390053 | 0.79 | ELANE (0.58) | KMT2AELANEHSD17B10ALDH1A1RAB9A | |
| SCHEMBL11876667 | 0.79 | ELANE (0.58) | KMT2AELANEHSD17B10ALDH1A1RAB9A | |
| SCHEMBL9733951 | 0.79 | KMT2A (0.51) | KMT2AHSD17B10PDE4BCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| EP-2350000-A1 | PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010028776-A1 | PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-18 | — | — | WO | disclosed |
| EP-2163541-A1 | Piperazine derivatives for binding and imaging amyloid plaques and their use | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | APP, APBA1, PSEN1 | KMT2A 4443/4885ELANE 1915/4885HSD17B10 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.